Revamping the Clinical Trials System
As cooperative groups begin to merge, priorities and funding patterns are being redrawn When the National Cancer Institute (NCI) started its clinical trials cooperative groups in 1955, few people believed that smoking caused lung cancer and radical surgeries to extirpate cancer were the norm. Since then, findings from studies undertaken by the cooperative groups have shaped oncology practice and prolonged the lives of cancer patients by identifying and evaluating new treatments. But the operation of the cancer clinical trials system hasn't kept pace with the science.
Last year the Institute of Medicine (IOM) reported that the cooperative group program "is falling short of its potential" and is "approaching a state of crisis." The analysis noted that designing and initiating a trial can take years due to lengthy and redundant steps in the approval process. Some trials never open because the questions they seek to answer are no longer relevant by the time they receive approval. It also declared that the system lacks a suitable process of prioritizing and selecting trials as well as adequate funding.
NCI and the cooperative groups themselves have started to address many of the report's recommendations, including the consolidation of 10 existing cooperative groups into 5-4 dedicated to cancer in adults and 1 to cancer in children. Merging the groups, many researchers say, will lead to greater efficiencies in the development and conduct of clinical trials.
The first new group emerged in July: the Alliance for Clinical Trials in Oncology. That's the new name for the American College of Surgeons Oncology Group (ACOSOG), Cancer and Leukemia Group B (CALGB), and North Central Cancer Treatment Group (NCCTG), which have joined forces.
"Each of our individual groups has scientific and organizational strengths," says former ACOSOG co-chair Heidi Nelson, a professor of surgery at Mayo Clinic. "We are optimistic that when we join together, the sum will be greater than the individual parts, and the new scientific opportunities will advance patient care."
The American College of Radiology's Imaging Network (ACRIN) and the Eastern Cooperative Oncology Group (ECOG) will merge their research programs. So will the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the Radiation Therapy Oncology Group (RTOG). Members of the Gynecologic Oncology Group (GOG) may partner with one of the newly formed groups. SWOG, formerly the Southwest Oncology Group, plans to maintain its current structure. The Children's Oncology Group (COG), the only pediatric group, is not affected by this consolidation.
As they consolidate, the groups will standardize their protocols, auditing rules, and consent forms. They will register clinical trial participants using common information systems. Additionally, the groups will share resources such as tissue specimens. Clinical trials already under way will continue to follow their existing processes so as not to disrupt critical research. 
